<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3033">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04305106</url>
  </required_header>
  <id_info>
    <org_study_id>QLEmer</org_study_id>
    <nct_id>NCT04305106</nct_id>
  </id_info>
  <brief_title>Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT</brief_title>
  <acronym>BEST-RCT</acronym>
  <official_title>The Efficacy and Safety of Bevacizumab in Severe or Critical Patients With COVID-19--a Multicenter Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Renmin Hospital of Wuhan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ialy Moriggia Pelascini Gravedona Hospital S.p.A</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangbei Union Hospital of Huazhong University of science and technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Provincial Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Qilu Hospital of Shandong University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The novel coronavirus (SARS-CoV-2) is a new strain of coronavirus found in human in 2019,&#xD;
      which causes epidemic worldwide. Novel coronavirus disease (COVID-19) causes acute lung&#xD;
      injury (ALI) and acute respiratory distress syndrome (ARDS) in the severe and critically&#xD;
      severe patients. Pulmonary edema is the key detrimental feature of ALI/ARDS. Autopsy of&#xD;
      patients died from COVID-19 reported that, pulmonary mucus exudation was severe, more obvious&#xD;
      than SARS infection. Pulmonary CT scanning and pathological findings also suggest that&#xD;
      pulmonary edema caused by inflammatory exudation is a distinguished feature of COVID-19.&#xD;
      However, specific pharmacotherapy is lacking.Vascular endothelial growth factor (VEGF) is&#xD;
      known as the most potent inducing factors to increase vascular permeability. Bevacizumab is&#xD;
      an anti VEGF recombinant humanized monoclonal antibody, which has been used in anti-tumor&#xD;
      treatment for 16 years. Evidence suggest that Bevacizumab is a promising drug for severe and&#xD;
      critical COVID-19 patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 17, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The time from randomization to clinical improvement</measure>
    <time_frame>No more than 28 days</time_frame>
    <description>The time from randomization to an improvement of two points on a seven-category ordinal scale or live discharge from the hospital</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>COVID-19 Pneumonia</condition>
  <arm_group>
    <arm_group_label>Bevacizumab Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab 7.5mg/kg body weight + 0.9% NaCl 100ml, intravenous drip</description>
    <arm_group_label>Bevacizumab Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 18-80 years old, male and female;&#xD;
&#xD;
          2. Covid-19 confirmed cases;&#xD;
&#xD;
          3. Comply with any of the following:&#xD;
&#xD;
               -  Dyspnea, RR ≥ 30 times / min;&#xD;
&#xD;
                    -  In resting state, transcutaneous oxygen saturation ≤ 93%;&#xD;
&#xD;
                         -  Oxygenation index (PaO2 / FiO2) &lt; 300MMHG;&#xD;
&#xD;
          4. Pulmonary imaging showed diffuse exudative lesions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unable to obtain informed consent;&#xD;
&#xD;
          2. Patients with severe liver dysfunction (Child Pugh score ≥ C, or AST &gt; 5 times of the&#xD;
             upper limit), severe renal dysfunction (estimated glomerular filtration rate ≤ 30ml /&#xD;
             min / 1.73 m2), or continuous renal replacement therapy, hemodialysis, peritoneal&#xD;
             dialysis;&#xD;
&#xD;
          3. Patients with hypertension and unsatisfactory control of antihypertensive drugs&#xD;
             (sitting systolic blood pressure &gt; 160mmHg, or diastolic blood pressure &gt; 100mmHg) had&#xD;
             a history of hypertension crisis or hypertensive encephalopathy;&#xD;
&#xD;
          4. Patients with heart disease or clinical symptoms that can not be well controlled, such&#xD;
             as NYHA class II or above of cardiac insufficiency, unstable angina, myocardial&#xD;
             infarction within one year, supraventricular or ventricular arrhythmias need treatment&#xD;
             or intervention;&#xD;
&#xD;
          5. Those with known hereditary bleeding tendency or coagulation dysfunction, those who&#xD;
             had received full dose anticoagulant or thrombolytic therapy in the first 10 days of&#xD;
             the group, or those who had taken nonsteroidal anti-inflammatory drugs with platelet&#xD;
             inhibition in the first 10 days of the group (except those who had preventive use of&#xD;
             low-dose aspirin ≤ 325mg / day);&#xD;
&#xD;
          6. In the first 6 months of the group, the patients who had thrombosis, such as ischemic&#xD;
             stroke, transient ischemic attack, deep vein thrombosis, pulmonary embolism and other&#xD;
             thrombotic diseases, and in the first 6 months of the group, the patients who had&#xD;
             serious angiopathy (including aneurysms or arterial thrombosis requiring surgical&#xD;
             treatment) were screened;&#xD;
&#xD;
          7. Patients with unhealed wounds, active gastric ulcer or fracture; patients with&#xD;
             gastrointestinal perforation, gastrointestinal fistula, abdominal abscess and internal&#xD;
             fistula in the first 6 months of the group; patients with major surgical history&#xD;
             (including thoracotomy biopsy), major trauma (such as fracture) or possible surgery in&#xD;
             the course of participating in the trial within 28 days before the group;&#xD;
&#xD;
          8. There were hemoptysis, gastrointestinal bleeding, central nervous system bleeding,&#xD;
             nose bleeding and other serious and active bleeding patients within one month before&#xD;
             admission;&#xD;
&#xD;
          9. There were malignant tumors in the past 5 years;&#xD;
&#xD;
         10. Those allergic to bevacizumab and its components;&#xD;
&#xD;
         11. Untreated active hepatitis patients and HIV positive patients;&#xD;
&#xD;
         12. Pregnant women, lactating women and planned pregnant women;&#xD;
&#xD;
         13. Have participated in other clinical trials or the researchers think it is not suitable&#xD;
             to participate in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yihai Cao, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qilu Hospital of Shandong University, Karolinska Institutet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yuguo Chen, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qilu Hospital of Shandong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiaojiao Pang, Dr</last_name>
    <phone>18560089129</phone>
    <email>jiaojiaopang@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiaojiao Pang, Dr</last_name>
      <phone>+86 18560089129</phone>
      <email>jiaojiaopang@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 9, 2020</study_first_submitted>
  <study_first_submitted_qc>March 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2020</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

